Our nephrologist, Dr. Vanesa Pomeranz, will be available from 10:00 a.m. to 12:00 p.m. on Thursday, October 22 and Friday, October 23 to discuss your renal trials at Booth 1039.
Meet Emerald Clinical’s Experts at ASN Kidney Week
Denver, CO, October 22-25, 2026
Booth 1039
Book a Meeting with Us
Advancing to Next-Gen Precision Nephrology
Nephrology is changing fast. Medicine is moving away from broad, one-size-fits-all treatments. The future belongs to genetic targeting, omics signatures, and precise patient phenotyping. Emerald bridges the gap between these complex scientific insights and seamless clinical execution.
Why Partner with Emerald?
Global Patient Access
- Rare Disease Reach: Connect with hard-to-find CKD and orphan renal populations globally.
- Rapid Enrollment: Accelerate timelines despite highly restrictive protocol criteria.
- Diverse Cohorts: Tap into established, global investigator networks.
Deep Scientific Expertise
- Indication Experience: Proven track record in CKD, IgA Nephropathy, FSGS, PMN, C3G, AKI, and PKD.
- Cross-Specialty Synergy: Deep therapeutic knowledge in immuno-nephrology and cardio-renal-metabolic studies.
- Strategic Advisory: Access to senior scientific leadership and clinical development advisory boards.
Operational Precision
- Flawless Data Quality: Maintain high data integrity across long, complex protocol designs.
- Adaptive Trial Execution: Deploy flexible methodologies to pivot as data emerges.
- Patient Stratification: Seamlessly manage complex omics data (genomics, proteomics, transcriptomics) to identify target populations.
Watch our Latest On-demand Webinar:
The Glomerular Revolution: Understanding the New Wave of Breakthroughs in Rare Kidney Diseases
Book a Meeting with Our Experts
Learn more about our Renal Capabilities.
Claudio Hegenberger MD, MBA, MSc
Vice President, Scientific and Medical Affairs
Molly Bur Kitten
Senior Project Director, Scientific and Medical Affairs
Chelsey Hehl
US/EU Therapeutic Franchise Head for Renal Strategy
Vanesa Pomeranz
Senior Medical Monitor
Sergio Godoy
Director, Scientific and Medical Affairs
Read our Renal Study Success Stories
We work to keep every patient engaged to the end, from risk…
Accelerated execution enabled patient enrollment one year ahead of schedule
KOLs in 26 countries exceed expectations with proven strategies and communication network
Study helps yield full approval for investigative product by FDA for IgAN…
At the peak of the COVID pandemic, recruitment was met, and patient…
Emerald Clinical Renal Scientific Leadership Team Keeps Recruitment on Target in Difficult CKD Study
Despite operational delays, COVID interruptions and Ukraine war outbreak, targets were met.